Monitoring Anthracycline Cancer Drug-Nucleosome Interaction by NMR Using a Specific Isotope Labeling Approach for Nucleosomal DNA

Clara L. van Emmerik, Vincenzo Lobbia, Jacques Neefjes, Frank H.T. Nelissen, Hugo van Ingen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Chromatinized DNA is targeted by proteins and small molecules to regulate chromatin function. For example, anthracycline cancer drugs evict nucleosomes in a mechanism that is still poorly understood. We here developed a flexible method for specific isotope labeling of nucleosomal DNA enabling NMR studies of such nucleosome interactions. We describe the synthesis of segmental one-strand 13C-thymidine labeled 601-DNA, the assignment of the methyl signals, and demonstrate its use to observe site-specific binding to the nucleosome by aclarubicin, an anthracycline cancer drug that intercalates into the DNA minor grooves. Our results highlight intrinsic conformational heterogeneity in the 601 DNA sequence and show that aclarubicin binds an exposed AT-rich region near the DNA end. Overall, our data point to a model where the drug invades the nucleosome from the terminal ends inward, eventually resulting in histone eviction and nucleosome disruption.

Original languageEnglish
Article numbere202400111
JournalChemBioChem
Volume25
Issue number9
Early online date12 Mar 2024
DOIs
Publication statusPublished - 2 May 2024

Keywords

  • aclarubicin
  • conformation
  • DNA
  • NMR
  • nucleosome

Fingerprint

Dive into the research topics of 'Monitoring Anthracycline Cancer Drug-Nucleosome Interaction by NMR Using a Specific Isotope Labeling Approach for Nucleosomal DNA'. Together they form a unique fingerprint.

Cite this